The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation

Exclusion Criteria

• •1. Acute promyelocytic leukemia with PML-RARA fusion gene
• •2. Acute myeloid leukemia with RUNX1-RUNX1T1 or CBFB-MYH11 fusion gene
• •3. Acute myeloid leukemia with BCR-ABL fusion gene
• •4. Have treated patients (those who have previously received induction chemotherapy but can receive hydroxyurea down-cell therapy).
• •5. Concurrent malignant tumors of other organs (those requiring treatment).
• •6. Active heart disease, defined as one or more of the following:
• •1\) A history of uncontrolled or symptomatic angina; 2) Myocardial infarction less than 6 months after enrollment; 3) Have a history of arrhythmia requiring drug treatment or severe clinical symptoms; 4) Uncontrolled or symptomatic congestive heart failure (\> NYHA level 2); 5) The ejection fraction is lower than the lower limit of the normal range. 7. Serious infectious diseases (uncured tuberculosis, pulmonary aspergillosis). 8. Those who were not considered suitable for inclusion by the researchers.